Last year, Motilal Oswal’s 18th Wealth Creation Study gave us five multi-bagger stocks on a platter. If we didn’t act on the advice and grab the stocks, we have ourselves to blame. We should not miss out on such opportunities in future because even their current stock picks appear likely to outperform by a wide margin
Amar Ambani of IIFL has issued a “Call Success & Update” report claiming that PTC India Fin Services has given a return of 103% in 6 months. He has advised a further buy. He has also recommended a buy of JSW Steel for 28% upside
ET has collated a list of blue-chip stocks recommended by top brokerages which are ripe for a buy now
Gateway Distriparks is likely to be one of the big beneficiaries of the GST. Ace investors like Sankaran Naren and Akash Prakash are busy buying truckloads of the stock. We need to stay alert to the situation
JB Chem has been battered due to the currency crises in Russia. This presents an opportunity for us to tuck into this fundamentally strong Pharma company says Daljeet Kohli
ET has issued a report on the stocks that will benefit as a result of GST and which should be bought now
Sharekhan has issued a research report claiming that the the acquisition of Natrol is a positive development for Aurobindo Pharma and that the stock should be bought
Sharekhan has issued a report advising investors to book part profits from the huge run up in Gulf Oil Lubricants
Amar Ambani of IIFL has issued a “Call Success & Update Report” in which he claims that three stock recommendations have given good gains to date. He has advised further buying of these stocks for more gains
Daljeet Kohli has slashed the target price of Sharon Bio-Medicine from Rs. 140 to Rs. 66. Though there is still a huge potential upside, he has downgraded the stock to ‘Hold’ to await clarity of future events
Recent Comments